The ASCO 2022 annual meeting was held last month, and on June 3rd, the Goldkorn Lab presented an oral abstract showcasing research done in cooperation…
Category: Video
From CancerNetwork: “Men with metastatic castrate resistant prostate cancer (mCRPC) with undetectable circulating tumor counts (CTCs) were 6.1-fold more likely to have complete response to…
“Amir Goldkorn, MD, of USC Norris Comprehensive Cancer Center, discusses findings from SWOG S1216, which showed that using circulating tumor cell (CTC) count at…
Watch it here: New biomarker may guide initial treatment of metastatic prostate cancer – Keck Medicine of USC (broadcastmed.net) “Prostate cancer is the most common…